Clinical Evidence and Approval Background

The EMA recently evaluated that clinical data for Aidenalt (aflibercept) demonstrated significant improvements in visual acuity and safety compared to existing treatments for retinal vascular endothelial growth factor (VEGF) inhibitors. In key clinical trials, the rate of visual impairment progression was significantly lower in the patient group, and the incidence of adverse events was also reported to be low. These results were the core basis for the approval decision and are expected to greatly contribute to improving the quality of life for patients.

Positioning Compared to Competing Drugs

Aidenalt offers improved patient convenience compared to bevacizumab or ranibizumab, which are already on the market, due to its longer dosing interval. In addition, it has abundant long-term safety data, which has earned it trust among ophthalmologists. These differentiating factors are important considerations when selecting treatment options.

Reimbursement and Market Entry Challenges

European national health authorities require cost-effectiveness analysis when applying for new drug reimbursement, so Aidenalt's pricing policy will be an important variable. In some countries, reimbursement may be delayed due to the higher price compared to existing treatments. Therefore, the company needs to address the challenge of lowering market entry barriers through price negotiations and local partnerships.

Market Size and Growth Prospects

As stated in the original text, the retinal VEGF inhibitor market is estimated at several billion euros annually in Europe. Aidenalt's approval is likely to reshuffle market share, and it is expected to have high growth potential, especially in patient groups requiring long-term treatment. This is an important signal for both investors and researchers.